Superscript trial

By: NewsUSA

(NewsUSA) - For more details, including important safety information, on VenaSeal, visit: https://www.medtronic.com/breakfree.

Sources

1 Gloviczki P, Comerota AJ, Dalsing MC, et al. The care of patients with varicose veins and associated chronic venous diseases: Clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. J Vasc Surg. 2011;53(5 Suppl):2S–48S. doi: 10.1016/j.jvs.2011.01.079.

2 Mayo Clinic: Varicose Veinshttps://www.mayoclinic.org/diseases-conditions/varicose-veins/symptoms-causes/syc-20350643

3 National Heart Lung and Blood Institute: Varicose Veins https://www.nhlbi.nih.gov/health/varicose-veins

4 Morrison N, Gibson K, McEnroe S, et al. Randomized trial comparing cyanoacrylate embolization and radiofrequency ablation for incompetent great saphenous veins (VeClose). J Vasc Surg. 2015;61(4):985–994. doi: 10.1016/j.jvs.2014.11.071.

5 Proebstle T, Alm J, Dimitri S, et al. Three-year follow-up results of the prospective European multicenter cohort study on cyanoacrylate embolization for treatment of refluxing great saphenous veins. J Vasc Surg Venous Lymphat Disord. 2021;9(2):329–334. doi: 10.1016/j.jvsv.2020.05.019.

6 Almeida JI, Javier JJ, Mackay EG, Bautista C, Cher DJ, Proebstle TM. Thirty-sixth-month follow-up of first-in-human use of cyanoacrylate adhesive for treatment of saphenous vein incompetence. J Vasc Surg Venous Lymphat Disord. 2017;5(5):658–666. doi: 10.1016/j.jvsv.2017.03.016.

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  244.22
+3.28 (1.36%)
AAPL  262.19
-0.17 (-0.06%)
AMD  210.58
-3.77 (-1.76%)
BAC  56.06
-1.19 (-2.08%)
GOOG  321.96
+7.41 (2.36%)
META  653.25
-7.38 (-1.12%)
MSFT  488.49
+9.98 (2.09%)
NVDA  190.17
+2.93 (1.56%)
ORCL  193.74
-0.01 (-0.01%)
TSLA  436.92
+3.96 (0.91%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.